The
global liver diseases therapeutics market was worth USD 6.5 billion
in 2011 and is expected to reach USD 10.9 billion in 2018, growing at
a CAGR of 8.6% from 2012 to 2018. In the overall global market,
anti-viral drugs are expected to create its lead position in terms of
revenue generation by 2018. Anti-viral drugs will have a share of
32.7% of the global market followed by vaccines at 19.1% in 2018.
Browse
the full report at Liver Diseases Therapeutics Market
http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
The
major drivers of the global liver disease therapeutics market are
increasing aging population inducing chronic diseases such as
hepatitis and liver cancer, increasing global prevalence of liver
disorder, high unmet needs existing in liver cancer and increased
vaccination in emerging economies. However side-effects and risks
associated with the medication, strict FDA approval norms and other
government regulations and availability of alternate treatment
procedures may act as the barrier for this market. Strong pipeline
drugs and consolidation opportunities in the healthcare industry will
pose future growth prospect for this market.
Anti-viral
drugs represent the largest market in the liver disease therapeutics,
which is justified by the fact that many oral, direct-acting
antiviral medications are in development phase for treating hepatitis
C. Currently, anti-virals are only available for hepatitis B and C.
However, many anti-viral hepatitis C pipeline drugs namely GS-7977
(Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir (NS5a
Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease
Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to
accelerate this market in near future.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=799
The
major players in the liver diseases therapeutics market include
Astellas Pharma Inc, Gilead Science Inc, Merck & Co.,
Bristol-Myers Squibb, Novartis, Pfizer and Roche. In 2011, Astellas
was the market leader in the immunosuppressants drugs market for
liver diseases followed by Pfizer. In liver disease vaccines market,
GlaxoSmithKline Pharmaceuticals Limited (GSK) represented as the
major market player with a share of 45% in 2011. Bristol Myers Squibb
had the largest market share in anti-viral drugs market for liver
diseases followed by Gilead science in 2011.
Browse
all Press Releases:
http://www.transparencymarketresearch.com/press-releases.htm
This
research is specially designed to estimate and analyze the demand for
liver diseases therapeutics in global market. The research provides
an in-depth analysis of the product sales, drugs class wise trend
analysis and the major player pertaining to this market. High level
analysis of the mentioned drug class of global liver diseases
therapeutics market is performed and the report provides detailed
analysis, comprehensive historical data and statistically tested
forecast of the drug classes thus covered. Detailed qualitative
information is given for different liver diseases and the application
of different drugs as the treatment and therapy option.
Browse
all Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are
privileged with highly experienced team of Analysts, Researchers, and
Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Sheela
AK
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
No comments:
Post a Comment